Jose Calle Gordo

Mr. Calle Gordo brings 30 years of broad business and management experience in the medical device industry, having served in various executive and managerial roles at Biosensors, Abbott, Guidant, and Eli Lilly.

Up to recently, he was Vice Chairman of the Board of Directors of Biosensors, where he last served as Executive Director and CEO. During his tenure, based in Singapore, he turned around the company’s operating performance, forged strategic alliances, and worked with the largest shareholder to successfully privatize and delist the company in order to create a 1$Bn value global player in interventional cardiology.

He previously led the global team that developed Xience™, a family of drug-eluting stents and market leader for the treatment of coronary artery disease, while serving as Vice President and General Manager of Drug Eluting Stents, Vascular Intervention at Guidant based in California.

As Vice President of Abbott Vascular, based in Brussels, he later managed the international operations of Abbott Vascular outside of the US and led globally the commercial introduction of MitraClip™, a percutaneous treatment for mitral valve repair.

Mr. Calle Gordo also serves as the Chairman of Highlife Medical and serves on the Boards of Lungpacer, FEops, Laminate Medical, and SMT Medical.

Mr. Calle Gordo graduated from Universidad Politecnica de Madrid, Spain, in Biomedical and Electrical Engineering.